NVO FDA decision — Mar 3, 2026
✓ APPROVED
Novo Nordisk A/S — Sogroya (somapacitan) - (REAL8) · Noonan syndrome (NS).
Run-up into the decision (T-120 → T+5) PDUFA 3/3/26 $63.98 $37.45 9/16/25 Daily close, T-120 (9/16/25) through T+5. Run-up high $63.98 on 1/27/26, low $37.45 on 2/27/26 (T-120 to T-1). FDA decision 3/3/26. Historical price action, not a forecast.
Key facts
FDA decision date 2026-03-03
Outcome Approved
Drug / candidate Sogroya (somapacitan) - (REAL8)
Company Novo Nordisk A/S
120-day run-up (T-120→T-1) -30.5%
Not affiliated with or endorsed by the FDA. Informational and educational only — not investment advice. Verify against primary FDA / SEC / company filings. © 2026 pdufa.bio